Pro Medicus Strengthens FY27 Outlook as AI and Cloud Opportunities Expand
Pro Medicus Limited (ASX: PME) reported a strong FY26 performance, with management stating that revenue and profit growth remained on track on a constant-currency basis. The company recorded its second-largest year for new contracts, alongside six major renewals and a particularly busy implementation period. Several late-FY26 implementations are expected to contribute more significantly to transaction revenue during FY27.
The company remains confident about its positioning in AI-powered healthcare, with its Visage platform providing a gateway for image-based AI applications. Pro Medicus said its platform is now used by approximately 11% of the US market, including 11 of the country's top 20 healthcare institutions.
Growth opportunities are also emerging from cardiology, digital pathology and AI-driven reporting. Digital pathology is already operating in Europe, while the AI reporting platform is planned for US deployment in the first half of calendar 2027. Meanwhile, strong renewals, growing cloud adoption and a robust pipeline continue to support the company's expansion outlook.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Pro Medicus Strengthens FY27 Outlook as AI and Cloud Opportunities Expand
Pro Medicus Limited (ASX: PME) reported a strong FY26 performance, with management stating that revenue and profit growth remained on track on a constant-currency basis. The company recorded its second-largest year for new contracts, alongside six major renewals and a particularly busy implementation period. Several late-FY26 implementations are expected to contribute more significantly to transaction revenue during FY27.
The company remains confident about its positioning in AI-powered healthcare, with its Visage platform providing a gateway for image-based AI applications. Pro Medicus said its platform is now used by approximately 11% of the US market, including 11 of the country's top 20 healthcare institutions.
Growth opportunities are also emerging from cardiology, digital pathology and AI-driven reporting. Digital pathology is already operating in Europe, while the AI reporting platform is planned for US deployment in the first half of calendar 2027. Meanwhile, strong renewals, growing cloud adoption and a robust pipeline continue to support the company's expansion outlook.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au